Lercanidipina Mylan Italia

Lercanidipine, the active ingredient in Lercanidipina Mylan Italia, is a calcium channel blocker presented as an oral tablet for oral use. It treats hypertension in adult patients by lowering elevated blood pressure and reducing cardiovascular risk.

GNH USA supplies Lercanidipina Mylan Italia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is a dihydropyridine calcium channel blocker indicated for the management of hypertension.

Hypertension: Lowers elevated blood pressure, helping to prevent stroke, myocardial infarction and other cardiovascular complications.

Lercanidipine may cause a range of adverse reactions. Most are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness or light‑headedness, especially after standing. - Tachycardia: increased heart rate. - Fatigue or general weakness.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Angioedema: swelling of the face, lips, tongue or throat. - Myocardial infarction: rare cases of heart attack. - Elevated liver enzymes: indicating possible hepatic involvement. - Severe allergic reactions: rash, itching, or anaphylaxis.

Before initiating therapy, clinicians should consider several safety aspects.

Monitor blood pressure: ensure adequate control without excessive lowering. Assess cardiac status: avoid use in patients with unstable angina or recent myocardial infarction. Use caution in hepatic impairment: dose adjustment may be required. Avoid abrupt discontinuation: tapering can prevent rebound hypertension. Pregnancy and lactation: consult a physician; limited safety data are available. Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine can interact with several drug classes, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations and risk of hypotension. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect.

Moderate Interactions (Monitor Closely):\n- Beta‑blockers: additive blood‑pressure‑lowering effect, may require dose adjustment. - Diuretics: can enhance orthostatic hypotension. - Simvastatin or other statins metabolised by CYP3A4: increased risk of myopathy; monitor lipid‑lowering therapy.